\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ chemotherapy\\ with\\ some\\ decrease\\ in\\ the\\ enhancing\\ portion\\ of\\ tumor\\ over\\ past\\ 6\\ months\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enhancing\\ lesions\\ in\\ the\\ hypothalamus\\ and\\ chiasm\\.\ \(0\)\
\-\ \\â\\€\\¢\\ elevated\\ signal\\ intensity\\ basal\\ ganglia\\ bilaterally\\,\\ likely\\ due\\ to\\ myelinopathic\\ changes\\.\ \(0\)\
\-\ neurofibromatosis\\ type\\ 1\\ with\\ hypothalmic\\ and\\ chiasmatic\\ glioma\ \(0\)\
\-\ \\â\\€\\¢\\ meningioma\ \(7\)\
\-\ \\â\\€\\¢\\ craniopharyngioma\ \(0\)\
\-\ \\â\\€\\¢\\ pituitary\\ adenoma\ \(1\)\
\-\ \\â\\€\\¢\\ neurofibromatosis\\ hamartoma\ \(0\)\
\-\ \\â\\€\\¢\\ neurofibromatosis\\ neoplasm\\ \\(astrocytoma\\)\ \(0\)\
\-\ 8\\ year\\ old\\ boy\\ with\\ a\\ known\\ diagnosis\\ presents\\ with\\ decreasing\\ visual\\ acutity\\.\ \(1\)\
\-\ this\\ child\\ was\\ known\\ to\\ have\\ neurofibromatosis\\ type\\ 1\\ \\(nf1\\ or\\ von\\ recklinghausen\\ disease\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.5195837003767442\ \(0\)\
\-\ myelinopathic\\:\\ 0\\.2094791285171336\ \(0\)\
\-\ hypothalmic\\:\\ 0\\.2094791285171336\ \(0\)\
\-\ acutity\\:\\ 0\\.2094791285171336\ \(0\)\
\-\ chiasmatic\\:\\ 0\\.18425184989460652\ \(0\)\
\-\ recklinghausen\\:\\ 0\\.18071210963321846\ \(0\)\
\-\ type\\:\\ 0\\.17574419025005603\ \(0\)\
\-\ known\\:\\ 0\\.1696116652795283\ \(0\)\
\-\ enhancing\\:\\ 0\\.1641129582237715\ \(0\)\
\-\ hypothalamus\\:\\ 0\\.15902457127207942\ \(0\)\
\-\ nf1\\:\\ 0\\.15902457127207942\ \(0\)\
\-\ decreasing\\:\\ 0\\.1472945547128309\ \(0\)\
\-\ von\\:\\ 0\\.14510596053243827\ \(0\)\
\-\ chiasm\\:\\ 0\\.1390278628416776\ \(0\)\
\-\ hamartoma\\:\\ 0\\.12884400719653427\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.1265621311332921\ \(0\)\
\-\ ganglia\\:\\ 0\\.12311122215708806\ \(0\)\
\-\ pituitary\\:\\ 0\\.12082573813428417\ \(0\)\
\-\ decrease\\:\\ 0\\.11258716979216159\ \(0\)\
\-\ basal\\:\\ 0\\.11208614209241682\ \(0\)\
\-\ visual\\:\\ 0\\.11175809567641641\ \(0\)\
\-\ glioma\\:\\ 0\\.1112746492183109\ \(0\)\
\-\ child\\:\\ 0\\.10842870368210036\ \(0\)\
\-\ adenoma\\:\\ 0\\.10443068725843317\ \(0\)\
\-\ with\\:\\ 0\\.10259674395457727\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.09888446394742433\ \(0\)\
\-\ meningioma\\:\\ 0\\.09815251804162742\ \(0\)\
\-\ portion\\:\\ 0\\.093667670782011\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.09301050120295522\ \(0\)\
\-\ intensity\\:\\ 0\\.09301050120295522\ \(0\)\
\-\ boy\\:\\ 0\\.0896048359515165\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0894194013617058\ \(0\)\
\-\ elevated\\:\\ 0\\.0892966050338692\ \(0\)\
\-\ available\\:\\ 0\\.08887191654823837\ \(0\)\
\-\ bilaterally\\:\\ 0\\.0873598911696345\ \(0\)\
\-\ past\\:\\ 0\\.0852635791975001\ \(0\)\
\-\ some\\:\\ 0\\.08241668820133748\ \(0\)\
\-\ changes\\:\\ 0\\.07916398740977229\ \(0\)\
\-\ likely\\:\\ 0\\.07827549012163823\ \(0\)\
\-\ months\\:\\ 0\\.07624590477996475\ \(0\)\
\-\ due\\:\\ 0\\.07529464444379254\ \(0\)\
\-\ lesions\\:\\ 0\\.07522818170974377\ \(0\)\
\-\ signal\\:\\ 0\\.07425365674580693\ \(0\)\
\-\ over\\:\\ 0\\.07283536510247993\ \(0\)\
\-\ tumor\\:\\ 0\\.06851458562817529\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0679035102236569\ \(0\)\
\-\ to\\:\\ 0\\.06549373562903815\ \(0\)\
\-\ have\\:\\ 0\\.0654359409055754\ \(0\)\
\-\ in\\:\\ 0\\.06517137559791422\ \(0\)\
\-\ presents\\:\\ 0\\.06301223007812327\ \(0\)\
\-\ disease\\:\\ 0\\.05498431909125479\ \(0\)\
\-\ and\\:\\ 0\\.05413433986797572\ \(0\)\
\-\ the\\:\\ 0\\.05227390433403408\ \(0\)\
\-\ not\\:\\ 0\\.0517111440924352\ \(0\)\
\-\ was\\:\\ 0\\.04565078925770857\ \(0\)\
\-\ or\\:\\ 0\\.045568566879328753\ \(0\)\
\-\ this\\:\\ 0\\.045010007668195844\ \(0\)\
\-\ year\\:\\ 0\\.04036807689894677\ \(0\)\
\-\ old\\:\\ 0\\.03876732757958825\ \(0\)\
\-\ of\\:\\ 0\\.02563386975757238\ \(0\)\
